Private capital is flowing into health, but without a clear picture of where it comes from or where it is most needed, investors cannot evaluate it. The 2027 G20 offers a chance to fix that.
There is an asymmetry at play in development finance, and it is impacting crucial investment in the health sector. Twenty-eight development finance institutions have agreed on 30 common indicators for measuring investment in information and communications technology. For health, they have agreed on just three: patients served, facilities accredited and number of accreditations. All three measure headcount and compliance; none measure health outcomes.
This asymmetry shows that health has never been organized as an asset class. Development banks each apply their own health lending criteria, and other investors have no common reference point. Neither the EU taxonomy for sustainable activities nor the G20 sustainable finance workstream includes health. Green finance has had market-built definitions since 2013 and an official EU classification since 2020. Health has no equivalent.
More money is not the answer
Finance ministers are used to requests for more money for health, which are more likely to be refused when budgets are tight. In 2022, health spending as a share of GDP fell in 33 out of 38 OECD countries and in 18 of the G20 members, even as ageing populations and chronic disease increase demands on health systems.
Nor does more money always buy better health. Some G20 economies spend several times more per person than peers, yet have shorter life expectancy. The OECD estimates that healthier populations and less wasteful spending, supported by digital transformation, could help hold health spending at 10.6% of GDP by 2040. Without major policy change, it could reach 11.8%. For finance ministries, that 1.2 percentage points of GDP is a clear argument for spending more wisely.
Why capital stays away
Ask an asset manager why health is marginal in sustainable finance and the answer is rarely returns: every $1 invested in improving population health is estimated to generate $2 to $4 in economic benefit.
Rather, health is hard to underwrite: it is a tag with no measure of performance behind it. Health projects sit inside social and sustainability bonds, each issuer decides what counts as a health investment, and an allocator cannot compare two health assets in one portfolio. A shared framework could help close these gaps and open up investment opportunities.
The G20 has done this before
In 2016, under China’s presidency, the G20 set up a Green Finance Study Group, co-chaired with the UK. Its report listed unclear definitions among the challenges holding back green investment. By convening the work, the G20 gave the issue official standing; standard setters did the rest.
Health today is where green finance was in 2016: market tools such as ICMA’s health category and the SASB Health Care standards exist, but no shared definition of a health investment does.
A framework built from what already exists
Our G20 & G7 Health and Development Partnership has developed a voluntary Health Investment Framework with a steering committee drawn from the European Investment Bank, the European Bank for Reconstruction and Development, Council of Europe Development Bank, the World Economic Forum, the OECD, the World Health Organization, the Milken Institute, PIMCO, UNICEF, the UN children’s agency and others.
It tests an investment through four layers: It starts with qualifying questions; then it applies six principles, including access to healthcare, outcomes, system resilience, health workforce, environmental integrity and governance; it then tests thresholds and guardrails; finally it applies a clear label of health-aligned, health-improving or not eligible.
Development banks can use it alongside their own eligibility criteria to bring private co-investment into projects they finance with governments. Institutional investors can label and compare health investments made outside development banks. Governments can see what private capital in their hospitals and clinics is paying for, and plan public spending around it.
It is built from standards institutions already apply, from the System of Health Accounts and the EU taxonomy to IFRS S1 and the ICMA bond principles.
The framework is not a request for funding. It does not promote privatization: private capital already flows into health systems, unclassified, and the framework’s exclusions rule out investments that undermine referral pathways or widen gaps in access. Nor is it a new reporting regime: it runs on disclosures institutions already make.
The opportunity in 2027
In October, alongside the IMF-World Bank Annual Meetings in Bangkok, we asked finance ministries, development banks, investors and companies: what would have to be true for you to use this framework, and what is the strongest argument against it?
Their answers shaped four asks of the G20:
The G20 Sustainable Finance Working Group should take up a common language for health investment under the UK (2027) and South Korean (2028) G20 presidencies.
Development finance institutions should extend their health indicators beyond headcounts and accreditations.
One sovereign or development bank should test the framework on a real transaction with investors.
Finance ministries should decide which existing incentives to attach to investments the framework classifies; without that, it becomes another label with no economic effect.
The moment is now. In 2027, the UK holds the G20 Presidency and the UN convenes its High-Level Meeting on Universal Health Coverage, with progress in the G20 finance track feeding directly into it. G20 finance ministers can use the UK’s presidency to take up a common language for health investment that governments, development banks and investors can all use.





